Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 579-585 , August 2009

True radiotracers: Cu-64 targeting vectors based upon bombesin peptide

  • Timothy J. Hoffman

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • ,
  • Charles J. Smith

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • Department of Molecular Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri School of Medicine, Columbia, MO 65211, USA
    • University of Missouri Research Reactor Center, University of Missouri, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Harry S. Truman Memorial VA Hospital, Research Service Room A005, 800 Hospital Drive, Columbia, MO 65201, USA. Tel.: +1 573 814 6000x53683; fax: +1 573 882 1663.

Received 3 February 2009 ,Revised 9 March 2009 ,Accepted 19 March 2009.

References 

  1. Carducci MA, DeWeese TL, Nelson WG, Simons JW, Sinibaldi V, et al. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin Oncol. 1996;23:56–62
  2. Newling DW. Second-line treatment of metastatic prostatic carcinoma. Urol Res. 1997;25:S73–S78
  3. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997;32:284–293
  4. Eary JF, Schroff RW, Abrams PG, Fritzberg AR, et al. Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med. 1989;30:25–32
  5. Fritzberg AR, Wilbur DS. Radiolabeling of antibodies for targeted diagnostics. In:  Torchilin VP editors. Targeted delivery of imaging agents. Boca Raton (Fla): CRC Press, Inc.; 1995;p. 83–101
  6. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med. 1992;33:803–814
  7. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713
  8. Krenning EP, de Jong M. Therapeutic use of radiolabelled peptides. Ann Oncol. 2000;11:267–271
  9. Blum JE, Handmaker H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr Pharm Des. 2002;8:1815–1826
  10. Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des. 2002;8:1827–1836
  11. Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med. 2001;45:189–200
  12. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-[123I-Tyr-3-]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  13. Forrer F, Waldherr C, Maecke HR, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26(1B):703–707
  14. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, et al. Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):976–977
  15. Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19(1):65–71
  16. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Bio. 2005;32:733–740
  17. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [99mTc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3. Cancer Res. 2003;63:4082–4088
  18. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7–14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A. 2007;104:12462–12467
  19. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327–1337
  20. Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4)bombesin by tumor cells. Prostate. 1994;25:29–38
  21. Corjay MH, Dobrzanski DJ, Way JM, Viallet J, Shapira P, et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem. 1991;266(28):18771–18779
  22. Giacchetti S, Gauville C, de Cremoux P, Bertin L, Berthon P, et al. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer. 1990;46(2):293–298
  23. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152–1159
  24. Rogers BE, Bigott HM, McCarthy DW, Manna DD, Kim J, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756–763
  25. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7–14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18(4):1110–1117
  26. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl Med. 2004;45(8):1390–1397
  27. Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol. 2006;33:371–380
  28. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–183
  29. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1–14). Bioconj Chem. 2007;18:724–730
  30. Ma L, Yu P, Veerendra B, Rold TL, Retzloff L, Prasanphanich AF, et al. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7–14]NH2 peptide conjugate, a high affinity-fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Mol Imaging. 2007;6:171–180
  31. Nijsen JFW, Krijer GC, van het Schip AD. The bright future of radionuclides for cancer therapy. Anti-Can Agents Med Chem. 2007;7:271–290
  32. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Bio. 1996;23:957–980
  33. Anderson CJ, Welch MJ. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev. 1999;99:2219–2234
  34. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45:469–477
  35. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465–1474
  36. Sprague Je, Peng Y, Sun X, Weisman GR, Wong EH, et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Can Res. 2004;10:8647–8682
  37. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, et al. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle–amide complexes as models of peptide conjugate imaging agents. J Med Chem. 2007;50:2527–2535
  38. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13:3–16
  39. Pippin CG, Kumar K, Mirzadeh S, Gansow OA. Kinetics of the isotopic exchange between copper(II) and copper(II) 1,4,7-triazacyclononane-N,N′,N′ triacetate. J Labelled Compd Radiopharm. 1991;30:221
  40. Gasser G, Tjioe L, Graham B, Belousoff MJ, Juran S, Walther M, et al. Synthesis, copper(II) complexation, 64Cu-labeling, and bioconjugation of a new bis(2-pyridylmethyl) derivative of 1,4,7-triazacyclononane. Bioconj Chem. 2008;19:719–730
  41. Kukis DL, Li M, Meares CF. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg Chem. 1993;32:3981–3982
  42. Geraldes CFGC, Marques MP, de Castro B, Pereira E. Study of copper(II) polyazamacrocyclic complexes by electronic absorption spectrophotometry and EPR spectroscopy. Eur J Inorg Chem. 2000;559–565
  43. Wieghardt K, Bossek U, Chaudhuri P, Herrmann W, Menke BC, Weiss J. 1,4,7-Triazacyclononane-N,N′,N′-triacetate (TCTA), a hexadentate ligand for divalent and trivalent metal ions. Crystal structures of [CrIII(TCTA)], [FeIII(TCTA)], and Na[CuII(TCTA)]●2NaBr●8H2O. Inorg Chem. 1982;21:4308–4314
  44. van der Merwe MJ, Boeyens JCA, Hancock RD. Crystallographic and thermodynamic study of metal ion size selectivity in the ligand 1,4,7-triazacyclononane-N,N′,N″-triacetate. Inorg Chem. 1985;24:1208–1213
  45. Prasanphanich AF, Retzloff L, Lane SR, Nanda PK, Sieckman GL, et al. In vitro and in vivo analysis of [64Cu-NO2A-8-Aoc-BBN(7-14)NH2]: a site-directed radiopharmaceutical for PET imaging of T-47D human breast cancer tumors. Nucl Med Biol. 2009;36(2):171–181
  46. Maecke H, Zhang H, Walter M. Metabolically stabilized DOTA-bombesin based peptides by amino acid modification in position 11. In: EANM Congress Helsinki, September 4–8. 2004;
  47. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707–6715

PII: S0969-8051(09)00084-5

doi: 10.1016/j.nucmedbio.2009.03.007

Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 579-585 , August 2009

Article Tools

* Image Usage & Resolution